2024
Ex Vivo Immunization: A Strategy for Immunization Against SARS-CoV-2
Singh H, Nuthalapati P, Yendapalli P, Sahu D. Ex Vivo Immunization: A Strategy for Immunization Against SARS-CoV-2. 2024, 258-271. DOI: 10.1039/bk9781837672813-00258.Peer-Reviewed Original ResearchPeripheral blood mononuclear cellsNatural killer cellsCell-mediated immunityBlood mononuclear cellsEnhanced immune responseNaive lymphocytesDendritic cellsKiller cellsT cellsAntigen presentationB cellsMononuclear cellsImmune responseSARS-nCoV-2Human hostSignaling cascadesSARS-CoV-2Global pandemic coronavirus diseaseVirion particlesImmunityMass immunizationAdverse effectsCoronavirus 2Pandemic coronavirus disease
2021
Association of hypercoagulation with severe acute respiratory syndrome coronavirus 2 infection
Nuthalapati P, Ghanta M, Natesh N, Bhaskar L. Association of hypercoagulation with severe acute respiratory syndrome coronavirus 2 infection. Blood Research 2021, 56: 61-64. PMID: 34083499, PMCID: PMC8246040, DOI: 10.5045/br.2021.2021011.Peer-Reviewed Original ResearchLevels of clotting factorsAcute respiratory syndrome coronavirus 2 infectionSevere acute respiratory syndrome coronavirus 2 infectionAssociation of hypercoagulabilityWorld Health OrganizationCoronavirus 2 infectionAntithrombotic treatmentThrombotic complicationsSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2Inflammatory changesRespiratory syndrome coronavirus 2Implementation of guidelinesClotting factorsPlatelet activationCerebrovascular accidentMyocardial infarctionSyndrome coronavirus 2Coronavirus disease 2019Cerebral vesselsPatientsThrombus formationHypercoagulabilityComplicationsCoronavirus 2
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply